Nutrients,
Год журнала:
2025,
Номер
17(9), С. 1505 - 1505
Опубликована: Апрель 29, 2025
Background:
Gut
microbiota
play
a
critical
role
in
mediating
the
bidirectional
association
between
cancer
and
depression.
Emerging
evidence
indicates
that
adjusting
dietary
component
intake
can
significantly
alter
gut
composition,
thereby
influencing
host’s
metabolism
immune
function.
Changes
their
metabolites
may
represent
key
factors
preventing
cancer–depression
comorbidity.
Methods:
English
publications
were
searched
databases
including
Web
of
Science,
Scopus,
PubMed
using
series
keywords:
“cancer”,
“depression”,
“gut
microbiota”,
“dietary
components”,
related
terms,
individually
or
combination.
The
search
focused
on
preclinical
clinical
studies
describing
regulatory
effects
interventions.
Results:
This
narrative
review
summarizes
associations
among
microbiota,
cancer,
depression,
synthesizes
current
modulatory
mechanisms
specific
interventions,
patterns,
probiotics,
prebiotics,
diet-derived
phytochemicals,
microbiota.
On
one
hand,
these
interventions
inhibit
abnormal
proliferation
signals
tumor
microenvironment
enhance
anticancer
responses;
other
they
modulate
neurotransmitter
homeostasis,
suppress
neuroinflammation,
improve
mood
behaviors
through
gut–brain
axis
interactions
mediated
by
microbial
metabolites.
Conclusions:
complex
require
further
clarification.
Modulating
composition
components
represents
novel
therapeutic
strategy
for
improving
Regulated
homeostasis
intestinal
barrier
function,
while
bidirectionally
another
via
systemic
circulation
axis,
both
depressive-like
patients
reducing
adverse
cancer.
Nature Neuroscience,
Год журнала:
2023,
Номер
26(7), С. 1281 - 1294
Опубликована: Июнь 19, 2023
Abstract
Dynamics
and
functions
of
neural
circuits
depend
on
interactions
mediated
by
receptors.
Therefore,
a
comprehensive
map
receptor
organization
across
cortical
regions
is
needed.
In
this
study,
we
used
in
vitro
autoradiography
to
measure
the
density
14
neurotransmitter
types
109
areas
macaque
cortex.
We
integrated
data
with
anatomical,
genetic
functional
connectivity
into
common
space.
uncovered
principal
gradient
expression
per
neuron.
This
aligns
hierarchy
from
sensory
cortex
higher
cognitive
areas.
A
second
gradient,
driven
serotonin
5-HT
1A
receptors,
peaks
anterior
cingulate,
default
mode
salience
networks.
found
similar
pattern
human
brain.
Thus,
may
be
promising
translational
model
serotonergic
processing
disorders.
The
gradients
enable
rapid,
reliable
information
slow,
flexible
integration
Journal of Psychopharmacology,
Год журнала:
2023,
Номер
37(3), С. 237 - 241
Опубликована: Март 1, 2023
It
has
been
over
50
years
since
the
original
serotonin
hypothesis
was
proposed
by
British
Psychiatrist
Alec
Coppen.
Recently,
some
authors
have
questioned
validity
of
hypothesis.
In
this
narrative
review,
we
summarise
evidence
for
depression,
focusing
on
psychopharmacology
and
molecular
imaging,
as
well
systems-level
neuroscience.
Molecular Psychiatry,
Год журнала:
2023,
Номер
28(8), С. 3149 - 3152
Опубликована: Июнь 15, 2023
A
recent
"umbrella"
review
examined
various
biomarkers
relating
to
the
serotonin
system,
and
concluded
there
was
no
consistent
evidence
implicating
in
pathophysiology
of
depression.
We
present
reasons
for
why
this
conclusion
is
overstated,
including
methodological
weaknesses
process,
selective
reporting
data,
over-simplification,
errors
interpretation
neuropsychopharmacological
findings.
use
examples
tryptophan
depletion
serotonergic
molecular
imaging,
two
research
areas
most
relevant
investigation
serotonin,
illustrate
this.
Frontiers in Psychiatry,
Год журнала:
2023,
Номер
14
Опубликована: Июнь 12, 2023
Psychedelic
therapy
has
witnessed
a
resurgence
in
interest
the
last
decade
from
scientific
and
medical
communities
with
evidence
now
building
for
its
safety
efficacy
treating
range
of
psychiatric
disorders
including
addiction.
In
this
review
we
will
chart
research
investigating
role
these
interventions
individuals
addiction
beginning
an
overview
current
socioeconomic
impact
addiction,
treatment
options,
outcomes.
We
start
by
examining
historical
studies
first
psychedelic
era
mid-late
1900s,
followed
available
real-world
gathered
naturalistic,
observational,
survey-based
studies.
then
cover
modern-day
clinical
trials
therapies
first-in-human
to
phase
II
trials.
Finally,
provide
different
translational
human
neuropsychopharmacology
techniques,
functional
magnetic
resonance
imaging
(fMRI)
positron
emission
tomography
(PET),
that
can
be
applied
foster
mechanistic
understanding
therapeutic
mechanisms.
A
more
granular
effects
psychedelics
facilitate
optimisation
drug
development
landscape,
ultimately
improve
patient
Frontiers in Microbiology,
Год журнала:
2023,
Номер
14
Опубликована: Май 10, 2023
Depression
is
a
common
psychological
disease,
which
has
become
one
of
the
main
factors
affecting
human
health.
It
serious
impact
on
individuals,
families,
and
society.
With
prevalence
COVID-19,
incidence
depression
further
increased
worldwide.
been
confirmed
that
probiotics
play
role
in
preventing
treating
depression.
Especially,
Bifidobacterium
most
widely
used
probiotic
positive
effects
treatment
The
mechanisms
underlying
its
antidepressant
might
include
anti-inflammation
regulation
tryptophan
metabolism,
5-hydroxytryptamine
synthesis,
hypothalamus-pituitary–adrenal
axis.
In
this
mini-review,
relationship
between
was
summarized.
hoped
-related
preparations
would
prevention
future.
Frontiers in Psychiatry,
Год журнала:
2024,
Номер
14
Опубликована: Янв. 11, 2024
Background
Due
to
their
potential
impact
on
mood
and
wellbeing
there
has
been
increasing
interest
in
the
of
serotonergic
psychedelics
such
as
N,N-dimethyltryptamine
(DMT)
treatment
major
depressive
disorder
(MDD).
Aim
The
aim
Part
A
this
study
was
evaluate
safety,
tolerability,
pharmacokinetics
(PK)
pharmacodynamic
(PD)
profile
escalating
doses
SPL026
(DMT
fumarate)
psychedelic-naïve
healthy
participants
determine
a
dose
for
administration
patients
with
MDD
subsequent
Phase
2a
part
trial
(Part
B:
not
presented
manuscript).
Methods
In
1,
randomized,
double-blind,
placebo-controlled,
parallel-group,
single
dose-escalation
trial,
were
randomized
placebo
(
n
=
8)
or
four
different
[9,
12,
17
21.5
mg
intravenously
(IV)]
6
each
dose)
together
psychological
support
from
2
therapy
team
members.
PK
acute
(immediately
following
dosing
experience)
psychometric
measures
[including
mystical
experience
questionnaire
(MEQ),
ego
dissolution
inventory
(EDI),
intensity
rating
visual
analogue
scale
(IRVAS)]
determined.
Additional
endpoints
measured
longer-term
change
baseline
days
8,
15,
30
90.
These
included
Warwick
Edinburgh
mental
Spielberger’s
state-trait
anxiety
inventory.
Results
well
tolerated,
an
acceptable
safety
profile,
no
serious
adverse
events.
There
some
evidence
correlation
between
maximum
plasma
concentration
increased
IRVAS,
MEQ,
EDI
scores.
trends
are
likely
require
confirmation
larger
sample
size.
Using
analysis
PD,
results,
most
provide
intense,
tolerated
experience.
Conclusion
Based
data
obtained
given
2-phase
IV
infusion
over
10
min
(6
mg/5
15.5
min)
selected
be
taken
into
B
(to
future
Clinical
registration:
www.clinicaltrials.gov
,
identifier
NCT04673383;
https://www.clinicaltrialsregister.eu
2020-000251-13;
https://www.isrctn.com/
ISRCTN63465876.
